Clinical Trials Arena on MSN17d
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
FierceBiotech18d
Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA
Tris Pharma’s opioid alternative has scored a ... to the FDA as the basis for potential approval,” Tris’ CEO Ketan Mehta said in the March 6 release. “If approved, cebranopadol has the ...
Hosted on MSN1mon
Tris Pharma reports positive data from Phase III acute pain therapy trial
Tris Pharma CEO and founder Ketan Mehta said: “We are excited by the results from the ALLEVIATE-1 trial demonstrating a strong level of pain relief. “The opioid crisis has highlighted the ...
Business Wire18d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of ...
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial ... FDA as the basis for potential approval,” said Ketan Mehta, CEO and founder of Tris.
Applied Clinical Trials Online17d
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...
Yahoo Finance17d
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma CEO Ketan Mehta said: “If approved, cebranopadol has the potential to redefine the standard of care for acute pain management, offering a first-in-kind treatment option for patients ...